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Background: Two studies have reported statistically significant associations between the use of cardiac glycosides
(CGs) and an increased risk of lung cancer. However, these studies had a number of methodological limitations.
Thus, the objective of this study was to assess this association in a large population-based cohort of patients.
Methods: We used the United Kingdom Clinical Practice Research Datalink (CPRD) to identify a cohort of patients,
at least 40 years of age, newly-diagnosed with heart failure, or supra-ventricular arrhythmia. A nested case–control
analysis was conducted where each incident case of lung cancer identified during follow-up was randomly
matched with up to 10 controls. Exposure to CGs was assessed in terms of ever use, cumulative duration of use
and cumulative dose. Rate ratios (RRs) with 95% confidence intervals (CIs) were estimated using conditional logistic
regression after adjusting for potential confounders.
Results: A total of 129,002 patients were included, and followed for a mean (SD) of 4.7 (3.8) years. During follow-up,
1237 patients were newly-diagnosed with lung cancer. Overall, ever use of CGs was not associated with an increased
risk of lung cancer when compared to never use (RR = 1.09, 95% CI: 0.94-1.26). In addition, no dose–response
relationship was observed in terms of cumulative duration of use and cumulative dose with all RRs around the
null value across quartile categories.
Conclusion: The results of this large population-based study indicate that the use of CGs is not associated with
an increased risk of lung cancer.
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Cardiac glycosides (CGs) are natural steroids, derived
from digitalis, that share a chemical structure with estro-
gens and are therefore considered phytoestrogens. The
CG family includes digoxin, digitoxin and lanatoside C
which remain important drugs in the treatment of atrial
fibrillation (AF), some types of heart failure (HF), atrial
flutter (AFl) and other supra-ventricular tachycardia
(SVT) [1,2].
Due to their ability to bind to estrogen receptors, [3]
there has been interest in assessing whether the use of
CGs is associated with the incidence of breast cancer.
[4-9] Namely, two case–control studies found that the* Correspondence: samy.suissa@mcgill.ca
1Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research,
Jewish General Hospital, Montreal H3T 1E2, Quebec, Canada
2Department of Epidemiology, Biostatistics and Occupational Health, McGill
University, Montreal, Quebec, Canada
Full list of author information is available at the end of the article
© 2014 Couraud et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.use of digoxin was associated with an increased risk of
breast cancer (RR: 1.30, 95% CI: 1.14-1.48 and RR: 1.39,
95% CI: 1.32-1.46), respectively. [4,5] There has also
been interest on the effects of CGs on the incidence of
lung cancer. Indeed, there are data supporting a role of
female sexual hormones on lung cancer carcinogenesis,
[10] which raises the hypothesis that the use of CGs may
be associated with an increased risk of lung cancer. The
main epidemiologic argument is the dramatic increase of
non-small cell lung cancer in women over the last decades.
[11] In addition, some observational studies found an
association between lung cancer and some reproductive
factors. [12-14] This biological rational is supported by the
finding that estrogen receptors are frequently expressed in
lung cancer tumors [15-17].
To date, only two only observational studies have inves-
tigated the link between the use of CGs and lung cancer
incidence. [11,12] In one study, the use of digitalis-relatedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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death from lung cancer. [11] In the other study, digitoxin
users were found to have a significantly higher incidence
of lung cancer compared to a matched control population
(standardized incidence ratio: 1.35, 95% confidence
interval [CI]: 1.04-1.74). [12] However, lung cancer was
a secondary outcome in these studies, and the models
were not adjusted for important potential confounders,
such as smoking.
Given the limited data assessing the association between
the use of CGs and the risk of lung cancer, we conducted
a large population-based study to investigate whether the
use of these drugs are associated with an increased risk of




This study was conducted using the United Kingdom
(UK) Clinical Practice Research Datalink (CPRD), formerly
known as the General Practice Research Database. The
CPRD is the world largest databank on primary care. Since
its inception in 1987, it systematically records medical diag-
noses and procedures, drug prescriptions issued by general
practitioners, patient characteristics (such as body mass
index [BMI]), and lifestyle factors (such as smoking and
alcohol use). [13] Currently, the CPRD contains data on
over 12 million patients registered with more than 650
participating general practices across the UK. Medical
diagnoses and procedures are coded using the Read
classification, and drugs are coded based on the UK Pre-
scription Pricing Authority Dictionary. Cancer diagnoses,
including lung cancer, in the CPRD have been shown to
have a high validity [14].
The study protocol was approved by the Independent
Scientific Advisory Committee of the CPRD and the
Research Ethics Board of the Jewish General Hospital,
Montreal, Quebec, Canada.
Study population
Within the CPRD population, we identified all patients
diagnosed for the first time with HF, AF, AFl and/or
SVT, between January 1, 1988 and December 31, 2010,
and followed until December 31, 2012. Cohort entry was
defined as the date of any of the previously considered
diagnoses, whichever appeared first in the patient’s medical
record. The cohort was then restricted to patients at least
40 years of age at cohort entry, and those with at least two
years of ‘up-to-standard’ medical history in the general
practice prior to cohort entry. In order to identify new users
of CGs during follow-up, we excluded all patients who pre-
viously received these drugs at any time prior to cohort
entry. Finally, we excluded all patients previously diagnosed
with any cancer (excluding non-melanoma skin cancer) atany time prior to cohort entry to ensure the identification
of incident cases of lung cancer during follow-up, and to
avoid the inclusion of patients with metastatic disease to
the lung from other cancer sites. Patients meeting the study
inclusion criteria were then followed until a first-ever
diagnosis of lung cancer, death from any cause, end of
registration with the general practice, or end of the study
period (December 31, 2012), whichever came first.
Case–control selection
Within the cohort defined above, we conducted a nested
case–control analysis, which produces odds ratios that
are unbiased estimators of rate ratios (RRs) (i.e. no need
for the rare disease assumption) [15].
Cases consisted of all those newly-diagnosed with lung
cancer during follow-up. Up to 10 controls were randomly
selected from the case’s risk set (i.e. subset of the cohort
still at risk of experiencing the outcome at the time of the
case’s event date), after matching on year of birth (±1 year),
sex, cohort entry date (±1 year), and duration of follow-
up. The date of each case’s lung cancer diagnosis defined
the index date, which was also assigned to the matched
controls. All controls were alive, not previously diagnosed
with lung cancer, and registered with their general practice
when matched to a given case. All analyses were restricted
to cases and matched controls with at least one year of
follow-up in the risk set, which was necessary for latency
considerations.
Exposure to cardiac glycosides
We obtained all prescriptions for CGs received between
cohort entry and index date. We excluded exposures initi-
ated in the year immediately prior to index date in order
to take into account a latency time window (lag time), and
to minimize reverse causality, where initiation or termin-
ation of a treatment may have been influenced by early
signs or symptoms of lung cancer.
For the primary analysis, exposure to CGs was defined
as receiving at least one prescription of digoxin, lanatoside
C, digitoxin, or digitalis, between cohort entry and the
year prior to index date. For the secondary analysis, we
assessed whether there was a dose–response relationship
in terms of CG cumulative duration of use and cumulative
dose. Therefore, for patients deemed to have ever used
CGs, we calculated their cumulative duration of use,
defined as the sum of the specified durations of all CGs
prescription received between cohort entry and index
date. Cumulative dose was computed by multiplying
the daily dose of each CG prescription by its specified
duration of use and then summing the total quantities
received between cohort entry and index date. Since
CGs include four different drugs, we used the “defined
daily dose” (DDD) equivalence to convert digitalis, digi-
toxin and lanatoside C in digoxin equivalents doses (the
Figure 1 Flow chart of the cohort. CPRD – Clinical Practice Research
Datalink; HF – Heart Failure; AF - Atrial fibrillation; AFl – Atrial Flutter;
SVT – Supra Ventricular Tachycardia; CGs – Cardiac Glycosides.
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digoxin was equivalent to 0.1 milligrams of digitoxin,
to 100 milligrams of digitalis, and to 1 milligrams of
lanatoside C. Cumulative duration of use and cumula-
tive dose were classified in quartile categories based on
the distribution of use in the controls.
Statistical analysis
Descriptive statistics were used to describe the character-
istics of the cohort, cases and matched controls. We used
conditional logistic regression to estimate RRs and 95%
CIs. In the primary analysis, we assessed whether the use
of CGs was associated with an increased risk of lung
cancer. In the second analysis, we determined whether
there was a dose–response relationship in terms of cu-
mulative duration of use and cumulative dose.
In addition to the matching variables (age, sex, year of
cohort entry, and duration of follow-up) on which the
logistic regression was conditioned, the models were
adjusted for the following potential confounders mea-
sured at least one year prior to index date: smoking
status, BMI (<18.50 kg/m2, 18.50-24.99 kg/m2, 25.00-
29.99 kg/m2, ≥ 30.00 kg/m2), indication of CG use (HF,
AF, AFl and/or SVT), excessive alcohol use, history of
tobacco-related conditions (chronic obstructive pulmon-
ary disease, ischemic heart disease, and vascular diseases),
history of lung diseases (pneumonia, tuberculosis, and his-
tory of chronic lung disease), and factors associated with
sexual hormonal disorders (hypothalamic, pituitary, testis,
ovarian and adrenal gland disorders as well as virilism,
hormonal infertility, secondary and primary hormonal de-
ficiency). We also adjusted for drugs potentially associated
with lung cancer incidence (also measured at least one year
prior to index date), which consisted of statins, aspirin,
oral anticoagulants and antiplatelets, non-steroidal anti-
inflammatory drugs, anti-hypertensives (diuretics including
spironolactone, calcium-channel blockers, angiotensin re-
ceptor blockers, angiotensin converting enzyme inhibitors,
and beta-blockers), oral bisphosphonates, anti-diabetic
drugs (metformin, sulfonylureas, insulins, thiazolidine-
diones, and other anti-diabetic agents), and amiodarone
(which is rather implicated in chronic interstitial pneu-
monia and commonly prescribed in supraventricular
arrhythmia). Variables with missing information were
coded with an ‘unknown’ category.
Sensitivity and subgroup analyses
We conducted two sensitivity analyses to assess the
robustness of the results. In the first, we varied the lag
period prior to index date from one year to six months
and two years. The shorter six-month lag period was
considered to account for lung cancer’s usual rapid
growth. In the second analysis, we additionally adjusted
the models for the use of hormone replacement therapyand estrogen-based contraceptives among the female sub-
group of cases and matched controls. We also conducted
a subgroup analysis, where we assessed whether smoking
status, which is the leading risk factor for lung cancer, was
an effect modifier of the association between the use of
CGs and lung cancer. For this analysis, effect modification
was assessed by including interaction terms in the model
between CG use and smoking. All analyses were con-
ducted with SAS version 9.3 (SAS Institute, Cary, NC).
Results
A total of 129,002 patients met the study inclusion criteria
(Figure 1). The cohort comprised 65,369 men (50.7%) and
the mean (standard deviation [SD]) age at cohort entry
was 73.9 (11.5) years. Overall, 69,865 (54.2%) patients
were diagnosed with AF, 55,240 (42.8%) with HF, and
6605 (5.1%) with AFl or SVT. Patients were followed
for a mean (SD) of 4.7 (3.8) years, generating 610,954
person-years of follow-up. A total of 1237 patients
Table 1 Characteristics of lung cancer cases and matched
controls
Characteristic Cases Controls
n = 1237 n = 12,320
Agea, mean (SD) 77.3 (8.1) 76.8 (8.0)
<50 years, n (%) 2 (0.2) 20 (0.2)
50-70 years, n (%) 248 (20.0) 2695 (21.9)
>71 years, n (%) 987 (79.8) 9605 (78.0)
Malea, n (%) 818 (66.1) 8137 (66.0)
Follow-up time, yearsa; Mean (SD) 4.9 (3.2) 4.9 (3.2)
Smoking, n (%)
Never 134 (10.8) 4780 (38.8)
Everb 1031 (83.3) 6531 (53.0)
Unknown 72 (5.8) 1009 (8.2)
Excessive alcohol use, n (%) 143 (11.6) 970 (7.9)
Body mass index, n (%)
<18.5 kg/m2 29 (2.3) 172 (1.4)
18.5 to 24.9 kg/m2 365 (29.5) 3095 (25.1)
25.0 to 29.9 kg/m2 390 (31.5) 4150 (33.7)
≥ 30.0 kg/m2 241 (19.5) 2782 (22.6)
Unknown 212 (17.1) 2121 (17.2)
Cohort entry indicationc, n (%)
Chronic heart Failure 612 (49.5) 4782 (38.8)
Atrial fibrillation 561 (45.4) 6873 (55.8)
Atrial flutter or supra ventricular
tachycardia
64 (5.2) 665 (5.4)
Comorbidities, n (%)
Chronic obstructive pulmonary disease 428 (34.6) 1658 (13.5)
Heart and vascular diseases 697 (56.3) 6042 (49.0)
Pneumonia 740 (59.8) 5716 (46.4)
Tuberculosis 22 (1.8) 224 (1.8)
Other chronic lung diseases 333 (26.9) 2194 (17.8)
Sexual hormone disorders 7 (0.6) 84 (0.7)
Concomitant drugs, n (%)
Amiodarone 77 (6.2) 825 (6.7)
Non-steroid anti-inflammatory drugs 186 (15.0) 1954 (15.9)
Anti-hypertensives 1093 (88.4) 10701 (86.9)
Oral anticoagulants and antiplatelets 443 (35.8) 4941 (40.1)
Aspirin 578 (46.7) 5857 (47.5)
Statins 532 (43.0) 5240 (42.5)
Oral estrogen contraceptives and
hormone replacement therapyd
17 (4.1) 114 (2.7)
Anti-diabetic agents 143 (11.6) 1453 (11.8)
aMatching variables along with year of cohort entry.
bIncludes current and former smokers.
cDefined as the first ever recorded diagnosis.
dAmong women only.
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up, generating an incidence rate of 202/100,000 (95%
CI: 191–214) persons per year.
The characteristics of the cases and matched controls
are shown in Table 1. As expected, compared to con-
trols, lung cancer cases were more likely to have been
smokers, had a higher prevalence of COPD, history of
pneumonia, and chronic lung diseases.
The results of the primary and secondary analyses are
shown in Table 2. Overall, ever use of CGs was not asso-
ciated with an increased risk of lung cancer when com-
pared to never use (RR = 1.09, 95% CI: 0.94-1.26). In
addition, no dose–response relationship was observed in
terms of cumulative duration of use and cumulative dose
with all RRs around the null value across the quartile
categories. A total of 89 cases and 972 matched controls
and 16 cases and 207 matched controls used CGs for
more than 5 and 10 years. The use of CGs for at least 5
and 10 years was not associated with an increased risk
of lung cancer (RR: 1.04, 95% CI: 0.78-1.39 and RR: 0.79,
95% CI: 0.45-1.39, respectively). Only two controls were
exposed to digitoxin and lanatoside, while all other cases
and controls were exposed to digoxin only.
In sensitivity analyses, varying the lag period to six
month and 2 years produced results consistent with
those of the primary analysis (RR: 1.08, 95% CI: 0.94-1.24;
and RR: 1.02, 95% CI: 0.86-1.20, respectively). In the
female subgroup, further adjustment for hormone re-
placement therapy and estrogen contraceptives did not
materially change the results (Table 3). Finally, smok-
ing status was not an effect modifier of the association
between the use of CGs and lung cancer (see Table 4).
Discussion
The results of this large population-based study indicate
that the use of CGs and is not associated with an increased
risk of lung cancer in patients newly-diagnosed with HF,
AF, AFl or SVT. In addition, there was no evidence of a
dose- or duration-response relationship. Overall, the results
remained robust in sensitivity analyses.
While our findings suggest no association between the
use of CGs and lung cancer, two previous studies have
reported increased risks. [11,12] In the first study, the
authors calculated standardized mortality rates, using
computerized pharmacy records of 143,574 patients
from 1969 to 1973, which included 2,466 CG users. [11]
The authors reported significant associations between
215 drugs and 56 cancer sites. Among these drugs, the
use of CGs were associated with an increased risk for all
cancers, including lung cancer (SMR = 1.23 and 1.65
respectively, both p < .002, no 95% CIs were provided).
In the second study which used the Norwegian Cancer
Registry, users of CGs were found to have an increased risk
of lung cancer, when compared to the general population
Table 2 Crude and adjusted rate ratios for the association between the use of cardiac glycosides and lung cancer
incidence
Exposure to cardiac glycosides Cases Controls Crude RR Adjusted RR (95% CI)a
(n = 1237) (n = 12,320)
Overall
No use, n (%) 860 (69.5) 8528 (69.2) 1.00 1.00 (Reference)
Ever use, n (%) 377 (30.5) 3792 (30.8) 0.98 1.09 (0.94 - 1.26)
Cumulative duration of use
<14 months, n (%) 102 (8.2) 962 (7.8) 1.04 1.14 (0.91 - 1.45)
14 - 32 months, n (%) 102 (8.2) 931 (7.6) 1.10 1.21 (0.96 - 1.54)
32 - 60 months, n (%) 84 (6.8) 927 (7.5) 0.89 0.97 (0.75 - 1.25)
> 60 months, n (%) 89 (7.2) 972 (7.9) 0.89 0.99 (0.76 - 1.29)
Cumulative dose (in digoxin-equivalents)
< 60 mg, n (%) 121 (9.8) 1109 (9.0) 1.08 1.17 (0.94 - 1.45)
60 - 120 mg, n (%) 85 (6.9) 746 (6.1) 1.14 1.24 (0.96 - 1.59)
120 - 240 mg, n (%) 88 (7.1) 880 (7.1) 0.99 1.08 (0.84 - 1.39)
>240 mg, n (%) 83 (6.7) 1057 (8.6) 0.76 0.85 (0.65 - 1.11)
aAdjusted on smoking status BMI indication of CG use excessive alcohol use history of tobacco-related conditions history of lung diseases factors associated with
sexual hormonal disorders drugs potentially associated with lung cancer (statins aspirin oral anticoagulants and antiplatelets non-steroidal anti-inflammatory drugs
anti-hypertensives oral bisphosphonates anti-diabetic drugs) and amiodarone.
RR Rate ratio, CGs Cardiac Glycosides.
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[12] However, both of these studies had important
methodological limitations, such as lack of adjustment
for potentially important confounders, including smok-
ing, alcohol use, and comorbidity. [11,12] In contrast,
our analyses were adjusted for these variables, and re-
sidual confounding was further minimized by selecting
a cohort of patients with indications associated with the
use of CGs.
The lack of an association observed in our study is
supported by biological evidence. Estrogen receptors are
found on normal lung tissue samples, [16] and thus,Table 3 Crude and adjusted rate ratios for the association be
varying the lag period to 6 months and 2 years and by addit
Sensitivity analysis Cases
6-month lag period 1423
No use, n (%) 997 (70.1)
Ever use, n (%) 426 (29.9)
2-year lag period 990
No use, n (%) 703 (71.0)
Ever use, n (%) 287 (29.0)
Additionally adjusting for HRT/OC use in women 419
No use, n (%) 295 (70.4)
Ever use, n (%) 124 (29.6)
aAdjusted on smoking status BMI indication of CG use excessive alcohol use history
sexual hormonal disorders drugs potentially associated with lung cancer (statins asp
anti-hypertensives oral bisphosphonates anti-diabetic drugs) and amiodarone.
RR Rate ratio, HRT Hormone replacement therapy, OC Oral contraceptive).since lung is usually modulated by sex hormone, it can
be hypothesized that phytoestrogens would not specifically
induce cells or tissue damage (more than sex hormones
themselves). It is possible that sex hormones may act as
an oncogenic trigger in a small subset of patients, possibly
those predisposed to hormone-related cancers and
who carry some particular polymorphisms in estrogen
metabolism-related genes, as was previously suggested.
[17] This hypothesis may also explain conflicting results
regarding lung cancer risk and female reproductive fac-
tors. [10] Additional studies are needed to identify this
subset of patients.tween the use of cardiac glycosides and lung cancer by
ionally adjusting for sexual hormone intake in women
Controls Crude RR Adjusted RR (95% CI)a
14,166
9843 (69.5) 1.00 1.00 (Reference)
4323 (30.5) 0.97 1.08 (0.94 - 1.24)
9850
6815 (69.2) 1.00 1.00 (Reference)
3035 (30.8) 0.91 1.02 (0.86 - 1.20)
4183
2828 (67.6) 1.00 1.00 (Reference)
1355 (32.4) 0.88 0.97 (0.74 - 1.27)
of tobacco-related conditions history of lung diseases factors associated with
irin oral anticoagulants and antiplatelets non-steroidal anti-inflammatory drugs
Table 4 Effect modification by smoking status on the association between cardiac glycosides and lung cancer
incidence
Smoking status Cases Controls Adjusted RR (95% CI)a P value for interaction
Never 134 4780
No use, n (%) 92 3270 1.00 (Reference) 0.37
Ever use, n (%) 42 1510 1.08 (0.74-1.58)
Ever 1031 6531
No use, n (%) 722 4568 1.00 (Reference)
Ever use, n (%) 309 1963 1.06 (0.90-1.24)
Unknown 72 1009
No use, n (%) 46 690 1.00 (Reference)
Ever use, n (%) 26 319 1.55 (0.93-2.58)
aAdjusted on BMI indication of CG use excessive alcohol use history of tobacco-related conditions history of lung diseases factors associated with sexual hormonal
disorders drugs potentially associated with lung cancer (statins aspirin oral anticoagulants and antiplatelets non-steroidal anti-inflammatory drugs anti-hypertensives oral
bisphosphonates anti-diabetic drugs) and amiodarone.
RR Rate Ratio.
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cancer activity of CGs in vitro, and some derivatives of
CGs are currently being investigated for cancer therapies
in clinical trials. [18,19] CGs may act as inhibitors of
hypoxia-induced factors and inducers of immunogenic
cell death, possibly through the MAP Kinase pathway.
However, only a few clinical studies have assessed the
effect of CGs on oncogenesis, with heterogeneous find-
ings. Therefore, the potential of CGs as anticancer drugs
remains to be fully evaluated [20].
Our study has a number of strengths. First, we assem-
bled a cohort among patients newly-diagnosed with HF,
AF, AFl, or SVT. This was to minimize confounding by
indication, which was a limitation of the previous studies.
[11,12] Second, we matched controls to cases on year of
cohort entry, to minimize time trends in CG use and lung
cancer incidence in the 25-year study period. Indeed, in
UK as in most countries, CGs moved further down the
management pathway of HF and AF. [21,22] Third, the
models were adjusted for smoking status, which is the
major risk-factor for lung cancer which its absence was a
limitation in the previous studies on this subject. [11,12]
However, despite the availability of smoking status in the
CPRD, it was missing for 5.8% of cases and 8.2% of
controls. However, to minimize any residual confounding,
the models were additionally adjusted for smoking-related
diseases (COPD, heart and vascular diseases).
Our study also has some limitations. First, drug infor-
mation in the CPRD represents prescriptions written by
general practitioners. As such, it is unknown whether
prescriptions were actually filled at the pharmacy and
whether patients fully complied with the treatment
regimen. However, difference in compliance in not thought
to be differentially distributed among cases and controls
and should not have biased the results. Second, a limitation
of the CPRD is the lack of information on certain lungcancer risk factors, such as occupational exposures to
carcinogens, exposure to second-hand smoking, socio-
economic status, and family history of lung cancer.
[10,23] For women, additional reproductive factors
such as age at menopause or duration of sex life were
not taken into account. However, while these factors
may be weakly to moderately associated with lung cancer
incidence, we do not believe they are necessarily associ-
ated with the use of CGs, thus unlikely to strongly con-
found the association.
Conclusion
In summary, the results of this large population-based
study indicate that the use of CGs is not associated with
an increased risk of lung cancer. These findings should
provide reassurance to physicians and patients using these
agents.
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